Clinical Trial Update: Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating zoledronic acid given every 4 or 12 weeks to prevent skeletal-related events in advanced multiple myeloma; study completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Myeloma | Phase 4 | Status: COMPLETED | Results posted: 2021-05-26